Urovant Sciences Ltd (UROV) Stock Price & Overview

NASDAQ:UROV

16.24

+0.01 (+0.06%)

At close: Mar 26, 2021

16.23

-0.01 (-0.06%)

After Hours: 3/26/2021, 8:05:43 PM

Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

The current stock price of UROV is 16.24 null. Today UROV is up by 0.06%. In the past month the price increased by 0.43%. In the past year, price increased by 62.89%.

UROV Key Statistics

52-Week Range7.15 - 16.26

1-Month Range16.105 - 16.26

Market Cap: 531.746M
P/E: N/A
Fwd P/E: N/A
EPS (TTM): -5.14
Dividend Yield: N/A

UROV Stock Performance

Today

+0.06%

1 Week

N/A

1 Month

+0.43%

3 Months

+1.25%

Longer-term

6 Months +76.14%

1 Year +62.89%

2 Years N/A

3 Years N/A

5 Years N/A

10 Years N/A

UROV Stock Chart

Urovant Sciences Ltd / UROV Daily stock chart

UROV Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to UROV. When comparing the yearly performance of all stocks, UROV turns out to be only a medium performer in the overall market: it outperformed 43.41% of all stocks.

Chartmill TA Rating

Chartmill Setup Rating

UROV Full Technical Analysis Report

UROV Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to UROV. Both the profitability and financial health of UROV have multiple concerns.

Chartmill FA Analysis

Valuation

Growth

Profitability

Health

Dividend

UROV Full Fundamental Analysis Report

UROV Earnings

Next Earnings DateN/A

Last Earnings DateN/A

UROV Earnings History

UROV Forecast & Estimates

Analysts

Analysts60

Price TargetN/A

EPS Next Y-27.81%

Revenue Next YearN/A

UROV Forecast & Estimates

UROV Financial Highlights

Over the last trailing twelve months UROV reported a non-GAAP Earnings per Share(EPS) of -5.140000000000001. The EPS decreased by -25.06% compared to the year before.

Income Statements

Revenue(TTM)N/A

Net Income(TTM)-163.71M

		Industry Rank	Sector Rank
PM (TTM)	N/A
ROA	-150.35%
ROE	N/A
Debt/Equity	-1.44

Chartmill High Growth Momentum

EPS Q2Q%-7.35%

Sales Q2Q%N/A

EPS 1Y (TTM)-25.06%

Revenue 1Y (TTM)N/A

UROV financials

UROV Ownership

Ownership

Inst Owners19.1%

Shares32.74M

Float28.97M

Ins Owners70.43%

Short Float %N/A

Short RatioN/A

UROV Ownership

About UROV

Company Profile

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom.

Company Info

Urovant Sciences Ltd

11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR

LONDON X0 SW1Y 4LB

CEO: James Robinson

Phone: 44-0-20-7400-3347

Urovant Sciences Ltd / UROV FAQ

What does Urovant Sciences Ltd do?

Can you provide the latest stock price for Urovant Sciences Ltd?

The current stock price of UROV is 16.24 null. The price increased by 0.06% in the last trading session.

Does UROV stock pay dividends?

UROV does not pay a dividend.

How is the ChartMill rating for Urovant Sciences Ltd?

UROV has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.

Can you provide the market cap for Urovant Sciences Ltd?

Urovant Sciences Ltd (UROV) has a market capitalization of 531.75M null. This makes UROV a Small Cap stock.